Compare Equinor ASA (EQNR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs State Street SPDR S&P Biotech ETF — how do they compare? Equinor ASA trades at $35.55 (market cap $82.75B), while State Street SPDR S&P Biotech ETF trades at $151.97. The key difference: Equinor ASA pays a 4.24% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Equinor ASA nearer its low. Which is the better fit depends on your goals.
| EQNR | XBI | |
|---|---|---|
Market Cap | $82.75B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $42.40 | $164.28 |
52-Week Low | $22.41 | $85.16 |
Enterprise Value | $94.51B | — |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $35.78, down 1.13% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed recent earnings, beating expectations in Q1 2026 but missing in Q3 2025. Recent news highlights strategic investments in Norwegian Continental Shelf projects and a share buy-back program, while exiting non-core operations like Japan offshore wind.
EQNR presents a moderate investment case with a low P/E of 16.23 and strong cash flow, but faces risks from declining net income margins and volatile energy markets. Analyst sentiment is mixed with a 30% buy rating, suggesting cautious optimism amid execution and commodity price uncertainties.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
